HK1203949A1 - Inhibitors of iap - Google Patents

Inhibitors of iap Download PDF

Info

Publication number
HK1203949A1
HK1203949A1 HK15104538.4A HK15104538A HK1203949A1 HK 1203949 A1 HK1203949 A1 HK 1203949A1 HK 15104538 A HK15104538 A HK 15104538A HK 1203949 A1 HK1203949 A1 HK 1203949A1
Authority
HK
Hong Kong
Prior art keywords
compound
cell
iap
compounds
acid
Prior art date
Application number
HK15104538.4A
Other languages
English (en)
Chinese (zh)
Inventor
‧科昂
F‧科昂
‧加扎德
L‧J‧加扎德
‧徐
V‧H-W‧徐
‧弗吕加勒
J‧A‧弗吕加勒
Original Assignee
库里斯公司
遗传技术研究公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 库里斯公司, 遗传技术研究公司 filed Critical 库里斯公司
Publication of HK1203949A1 publication Critical patent/HK1203949A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0812Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0815Tripeptides with the first amino acid being basic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
HK15104538.4A 2012-01-03 2013-01-03 Inhibitors of iap HK1203949A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261582760P 2012-01-03 2012-01-03
US61/582,760 2012-01-03
PCT/US2013/020124 WO2013103703A1 (en) 2012-01-03 2013-01-03 Inhibitors of iap

Publications (1)

Publication Number Publication Date
HK1203949A1 true HK1203949A1 (en) 2015-11-06

Family

ID=48695302

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15104538.4A HK1203949A1 (en) 2012-01-03 2013-01-03 Inhibitors of iap

Country Status (41)

Country Link
US (6) US8716236B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP3133073B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP5747137B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (3) KR101855566B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN104159897A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (2) AR089623A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013202780B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014016637B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2861637C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2014001770A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO7020915A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CR (1) CR20140367A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY1118371T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK3133073T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (1) ECSP14011792A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2594856T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1203949A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (2) HRP20161381T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (2) HUE031305T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL242314A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (2) LT3133073T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA35895B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ME (2) ME03084B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX336294B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY178390A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO2755614T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ627480A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20142182A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (2) PH12014501534B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL2800749T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (2) PT2800749T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (2) RS57438B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (2) RU2593259C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG11201403784QA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (2) SI2800749T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SM (2) SMT201800352T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR201808088T4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI503318B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA114417C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013103703A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201405535B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2755614T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2012-01-03 2018-03-31
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
CN109705191B (zh) * 2017-10-25 2022-04-29 广东东阳光药业有限公司 Iap抑制剂及其在药物中的应用
ES2927195T3 (es) 2017-11-13 2022-11-03 Chia Tai Tianqing Pharmaceutical Group Co Ltd Miméticos de SMAC utilizados como inhibidores de IAP y uso de los mismos
US11639354B2 (en) 2018-07-31 2023-05-02 Fimecs, Inc. Heterocyclic compound
WO2021020585A1 (ja) 2019-07-31 2021-02-04 ファイメクス株式会社 複素環化合物
TW202133842A (zh) * 2019-12-02 2021-09-16 大陸商蘇州亞盛藥業有限公司 Iap抑制劑與parp或mek抑制劑或其他化學治療劑的組合
CN114980883A (zh) 2020-01-20 2022-08-30 阿斯利康(瑞典)有限公司 用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂
AU2022463015A1 (en) 2021-10-22 2024-05-09 Tract Pharmaceuticals, Inc. Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
DE69830577T2 (de) 1997-04-15 2006-05-04 Genentech, Inc., South San Francisco Halo-alkoxycarbonylverbindungen
RS53734B1 (en) * 2004-07-02 2015-06-30 Genentech Inc. IAP INHIBITORS
ZA200704910B (en) * 2004-12-20 2008-09-25 Genentech Inc Pyrrolidine inhibitors of IAP
EP2102229B1 (en) 2006-10-12 2014-03-26 Novartis AG Pyrrolydine derivatives as iap inhibitors
CA2683392A1 (en) 2007-04-30 2008-11-06 Genentech, Inc. Inhibitors of iap
NO2755614T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 2012-01-03 2018-03-31
USD690416S1 (en) 2012-12-12 2013-09-24 Pharmajet, Inc. Needle-free syringe

Also Published As

Publication number Publication date
ES2672809T3 (es) 2018-06-18
PH12014501534A1 (en) 2014-10-08
BR112014016637B1 (pt) 2022-06-14
NO2755614T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-03-31
RU2728789C2 (ru) 2020-07-31
TWI503318B (zh) 2015-10-11
CA2861637A1 (en) 2013-07-11
TW201333001A (zh) 2013-08-16
US9586991B2 (en) 2017-03-07
MX2014007895A (es) 2015-03-19
US20160102119A1 (en) 2016-04-14
KR20180051646A (ko) 2018-05-16
KR101855566B1 (ko) 2018-05-04
LT2800749T (lt) 2016-10-25
ME02526B (me) 2017-02-20
SMT201600357B (it) 2016-11-10
MX336294B (es) 2016-01-14
EP2800749B1 (en) 2016-09-21
JP5747137B2 (ja) 2015-07-08
MA35895B1 (fr) 2014-12-01
RU2014130171A (ru) 2016-02-27
EP3133073B1 (en) 2018-05-02
PE20142182A1 (es) 2015-01-16
HUE037760T2 (hu) 2018-09-28
BR112014016637A8 (pt) 2017-07-04
KR101917992B1 (ko) 2018-11-13
US20140235551A1 (en) 2014-08-21
BR112014016637A2 (pt) 2017-06-13
IL242314A (en) 2016-08-31
MY178390A (en) 2020-10-12
UA114417C2 (uk) 2017-06-12
ME03084B (me) 2019-01-20
US20190224269A1 (en) 2019-07-25
WO2013103703A1 (en) 2013-07-11
LT3133073T (lt) 2018-06-25
AR123542A2 (es) 2022-12-14
CR20140367A (es) 2015-02-18
SI2800749T1 (sl) 2016-11-30
PT2800749T (pt) 2016-10-24
US11096982B2 (en) 2021-08-24
PH12015501038A1 (en) 2015-09-21
KR20140107670A (ko) 2014-09-04
US11963994B2 (en) 2024-04-23
CN107915728A (zh) 2018-04-17
AR089623A1 (es) 2014-09-03
EP3133073A3 (en) 2017-03-22
RS55327B1 (sr) 2017-03-31
TR201808088T4 (tr) 2018-06-21
ES2594856T3 (es) 2016-12-23
EP3133073A2 (en) 2017-02-22
US20130172264A1 (en) 2013-07-04
RU2016124658A (ru) 2018-12-04
HRP20161381T1 (hr) 2016-12-02
US9238675B2 (en) 2016-01-19
IL233386A0 (en) 2014-08-31
PH12014501534B1 (en) 2014-10-08
US8716236B2 (en) 2014-05-06
CN104159897A (zh) 2014-11-19
AU2013202780A1 (en) 2013-07-18
PL2800749T3 (pl) 2017-01-31
RU2016124658A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2019-09-09
HUE031305T2 (hu) 2017-07-28
US20170136084A1 (en) 2017-05-18
IL233386A (en) 2016-08-31
ZA201405535B (en) 2017-08-30
HRP20180976T1 (hr) 2018-08-10
CO7020915A2 (es) 2014-08-11
EP2800749A1 (en) 2014-11-12
KR101553792B1 (ko) 2015-09-16
US20220211797A1 (en) 2022-07-07
CY1118371T1 (el) 2017-06-28
CY1120355T1 (el) 2019-07-10
PL3133073T3 (pl) 2018-09-28
ECSP14011792A (es) 2015-12-31
NZ627480A (en) 2016-04-29
CA2861637C (en) 2017-07-18
EP2800749A4 (en) 2015-08-05
KR20150065960A (ko) 2015-06-15
RU2593259C2 (ru) 2016-08-10
JP2015199738A (ja) 2015-11-12
RS57438B1 (sr) 2018-09-28
SI3133073T1 (en) 2018-06-29
DK2800749T3 (en) 2016-11-07
SMT201800352T1 (it) 2018-09-13
DK3133073T3 (en) 2018-06-18
SG11201403784QA (en) 2014-08-28
PH12015501038B1 (en) 2015-09-21
AU2013202780B2 (en) 2015-04-16
CN107915728B (zh) 2021-04-30
PT3133073T (pt) 2018-06-18
CL2014001770A1 (es) 2015-04-17
JP2015504072A (ja) 2015-02-05

Similar Documents

Publication Publication Date Title
US11963994B2 (en) Inhibitors of IAP
HK1253823A1 (en) Inhibitors of iap
HK1253823B (zh) Iap抑制剂
HK1234396A1 (en) Inhibitors of iap
HK1234396B (en) Inhibitors of iap